Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials. About Marinus Pharmaceuticals. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

Cannabis Law Report

JULY 19, 2021

Philip Morris International recently offered £1 billion to buy Vectura Group PLC, the British pharmaceutical company that develops inhaled medical products. The global market for inhalation drug delivery devices is predicted to reach $17.6 billion by 2027. About RYAH Group, Inc.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

AUGUST 25, 2021

The purchase and amalgamation of Consolidated Craft Brands was announced on March 19, 2021 bringing CPG and pharmaceutical manufacturing experience and Health Canada licenses for R&D. Actual results and future events could differ materially from those anticipated in such forward-looking statements. www.rapid-dose.com.

Events 111

Events Pharmaceutical Research and Development Business 111

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

OCTOBER 15, 2021

The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx. PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

JUNE 16, 2021

“Santé is a key partner to for Wake as they are a leading contract research organization (CRO) in Canada with expertise in advancing plant-based pharmaceutical products through various phases of clinical trial development.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JUNE 16, 2021

The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit www.trutrace.co.

Events 74

Events Access Legislation Conditions 74

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. and 43 international patent-pending applications, which provide patent protection for both PhAROS™, its proprietary drug discovery engine, and its novel, plant-inspired combination drugs for the treatment of more than 65 serious medical conditions.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 23, 2021

The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (LPs) to monitor and manage formulation effects on patients and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

AUGUST 25, 2021

The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient. www.rapid-dose.com.

Research and Development 111

Research and Development Events Business Access 111

Cannabis Law Report

DECEMBER 1, 2021

who has an extensive background in pharmaceutical research and development. This is an important step in the research protocol of our pharmaceutical program on JUVA-019,” said Doug Chloupek, CEO and Founder of Juva. The study will be conducted in-house via Juva’s research team, led by Dr. Sanjeev Gangwar, Ph.D., About Juva Life Inc.

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical THC 52

Cannabis Law Report

JANUARY 16, 2020

Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. Tweet this. About Devonian. Devonian Health Group Inc.

Extraction 64

Extraction Pharmaceutical Research and Development Terpenes 64

Cannabis Law Report

JUNE 10, 2021

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity.

eCommerce 61

eCommerce Research and Development Pharmaceutical Events 61

Cannabis Law Report

JUNE 1, 2021

The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and Licensed Processors (LPs) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

FEBRUARY 3, 2022

Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany. The closing of the transaction is subject to customary closing conditions. with growth of ~25% in 2021 compared to 2020 and a CAGR of ~55 % since 2017, making Germany one of the largest markets in Europe.

Pharmaceutical 52

Pharmaceutical Events Patients Medicine 52

The Joint Blog

DECEMBER 20, 2020

“Respondents reported a median score of 90 on a zero to 100-point scale in response to the question, “How does cannabis affect your conditions or symptoms overall?” Materials and Methods: A cross-sectional online survey of those using cannabis for health-related conditions run between May and July 2019.

Sleep 49

Sleep Data Pharmaceutical Marijuana 49

Veriheal

MARCH 18, 2021

Unfortunately, both of these conditions result in cognitive decline and suffer from a lack of effective treatment. This is a pretty common statement in most published research on cannabis as a possible treatment for conditions. Why Aging Cats?

CBD 95

CBD Research and Development Pets Treatment 95

Cannabis Law Report

DECEMBER 9, 2021

This novel technology will be welcomed in these markets as a truly innovative delivery mechanism, initially for nutraceuticals, with expansion into pharmaceuticals and vaccines to follow. Actual results and future events could differ materially from those anticipated in such forward-looking statements. www.rapid-dose.com.

Pharmaceutical 52

Pharmaceutical Research and Development Events Business 52